Literature DB >> 20494706

Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver.

John B Ammori1, Nancy E Kemeny.   

Abstract

Colorectal cancer metastases to the liver are primarily supplied by the hepatic artery. Therefore, delivery of regional chemotherapy via the hepatic artery is a viable treatment option. Chemotherapy can be delivered in high concentration to the liver with minimal systemic toxicity. Hepatic artery infusional (HAI) chemotherapy both alone and in combination with systemic chemotherapy in the treatment of isolated hepatic metastases from colorectal cancer has resulted in high response rates and increased resection rates for previously unresectable liver disease. Regional chemotherapy can also be used as adjuvant treatment after complete resection of liver metastases to reduce hepatic recurrences. The combination of HAI therapy with modern systemic chemotherapy has a role in the palliative, adjuvant, and neoadjuvant settings. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494706     DOI: 10.1053/j.seminoncol.2010.03.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

Review 1.  Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion.

Authors:  Alice Zervoudakis; Taryn Boucher; Nancy E Kemeny
Journal:  Visc Med       Date:  2017-02-03

Review 2.  Pectin matrix as oral drug delivery vehicle for colon cancer treatment.

Authors:  Tin Wui Wong; Gaia Colombo; Fabio Sonvico
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

3.  Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands.

Authors:  Florian E Buisman; Dirk J Grünhagen; Marjolein Y V Homs; Cecile Grootscholten; Wills F Filipe; Nancy E Kemeny; Andrea Cercek; Micheal I D'Angelica; Maarten L Donswijk; Leni van Doorn; Jasper Emmering; William R Jarnagin; T Peter Kingham; Elisabeth G Klompenhouwer; Niels F M Kok; Maria C Kuiper; Adriaan Moelker; Warner Prevoo; Michelle W J Versleijen; Cornelis Verhoef; Koert F D Kuhlmann; Bas Groot Koerkamp
Journal:  Ann Surg Oncol       Date:  2019-10-22       Impact factor: 5.344

4.  Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.

Authors:  Alice Boilève; Aline Maillard; Mathilde Wagner; Clarisse Dromain; Christophe Laurent; Eric Dupont Bierre; Samuel Le Sourd; Franck Audemar; Ayhan Ulusakarya; Veronique Guerin-Meyer; Denis Smisth; Veronica Pezzella; Thierry De Baere; Diane Goere; Maximiliano Gelli; Julien Taieb; Valérie Boige
Journal:  BMC Cancer       Date:  2020-01-30       Impact factor: 4.430

Review 5.  Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma.

Authors:  Adriana G Quiroz-Reyes; Jose F Islas; Paulina Delgado-Gonzalez; Hector Franco-Villarreal; Elsa N Garza-Treviño
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

6.  Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study.

Authors:  Hala Muaddi; Michael D'Angelica; Jason T Wiseman; Mary Dillhoff; Nicholas Latchana; Rachel Roke; Yoo-Joung Ko; Darren Carpizo; Kristen Spencer; Ryan C Fields; Gregory Williams; Federico Aucejo; Lou-Anne Acevedo-Moreno; Kevin G Billingsley; Brett S Walker; Skye C Mayo; Paul J Karanicolas
Journal:  J Surg Oncol       Date:  2020-10-23       Impact factor: 3.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.